|Articles|June 10, 2016
Oral Dose Development for Macromolecules
Author(s)Catalent Pharma Solutions
#wpbut {border: 3px solid #245998; border-radius:40px; border-color: #245998; padding: 15px 30px; font-size:15px !important;} #wpbut:hover {background: #15355a; color: #fff !important; transition: .5s;}
Related Content
Trending on Pharmaceutical Technology
1
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing
2
Ask the Expert: Complying with Standards
3
How the Nitrosamine Guidance Shift is Changing LC-MS Workflows for APIs and Peptides
4
Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models
5